# Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

> **NCT02370524** · PHASE1 · COMPLETED · sponsor: **Molecular NeuroImaging** · enrollment: 16 (actual)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** [18F]T807

## Key facts

- **NCT ID:** NCT02370524
- **Lead sponsor:** Molecular NeuroImaging
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370524, "Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02370524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*